AVADEL PHARMACEUTICALS PLC — Director's Dealing 2020

Sep 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2020-09-13

Reporting Person: McCamish Mark Anthony (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-13	Stock Option (right to buy)	$5.30	A	50000	Acquired	2030-09-13	ADSs (50000)	Direct

Footnotes

F1: The stock options shall vest and become exercisable in the following manner: 33% on September 13, 2021; 33% on September 13, 2022; and the remaining 34% on September 13, 2023.

F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.